Aeterna Zentaris Inc. (AEZS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2030 |
| Open | 0.2011 |
| Bid | 0.2068 x 1100 |
| Ask | 0.2069 x 800 |
| Day's Range | 0.1940 - 0.2128 |
| 52 Week Range | 0.1800 - 1.1500 |
| Volume | |
| Avg. Volume | 602,176 |
| Market Cap | 25.147M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0680 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- GlobeNewswire
Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (macimorelin) for Diagnosing Adult Growth Hormone Deficiency
TORONTO, ONTARIO, May 25, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Ghryvelin™ (macimorelin), the first oral test approved for diagnosing Growth Hormone Deficiency in adults (AGHD), is now available to healthcare professionals across Europe (subject to reimbursement). This availab
- GlobeNewswire
Aeterna Zentaris to Present at the H.C. Wainwright Global Investment Conference
TORONTO, ONTARIO, May 18, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually. In addition to the presentati
- GlobeNewswire
Aeterna Zentaris Announces Virtual 2022 Meeting of Shareholders and Urges Shareholders to Vote in Favor of the Proposed Share Consolidation
TORONTO, ON, May 16, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that its Virtual Annual General and Special Meeting of shareholders (the “AGM”) will be held on June 21, 2022, at 10:00 a.m. (ET). Management and the board of directors (the “Board”) urge the Company’s shareholders of record to vote “FOR” the resolution a
